At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
VEC-162drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of VEC-162 on Circadian Rhythm in Healthy Subjects
In Brief
A Phase 2 clinical trial evaluating VEC-162 for Circadian Rhythm Sleep Disorders. Completed, enrolled 45 participants across 2 sites.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of VEC-162 compared to matching placebo on circadian phase shift and sleep parameters.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCircadian Rhythm Sleep Disorders
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2004
Primary CompletionMar 2005
First PostedJun 2007
TodayJul 2026
First PostedJun 25, 2007
Enrollment StartJul 1, 2004
Primary CompletionMar 1, 2005
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 19.0 years ago
Interventions
VEC-162drug